Study of Effectiveness and Safety of SD-101 in Participants With Epidermolysis Bullosa

You may be eligible if

• Informed Consent form signed by the participant or the participant's legal representative; if the participant is under the age of majority but capable of providing assent, signed assent from the participant.
• Participant (or caretaker) was willing to comply with all protocol requirements.
• Diagnosis of Simplex, Recessive Dystrophic, or Junctional non-Herlitz EB.
• Participants 6 months of age and older.
• Participants had 1 target wound within a prespecified size range at study entry.
• Target wound was at least 21 days or older.
• Selected target wound had clinical evidence of local infection.
• Use of any investigational drug within 30 days before enrollment.
• Use of immunotherapy or cytotoxic chemotherapy within 60 days before enrollment.
• Use of systemic or topical steroidal therapy within 30 days before enrollment (inhaled steroids and ophthalmic drops containing steroids were allowed).
• Use of systemic antibiotics within 7 days before enrollment.
• Current or former malignancy.
• Arterial or venous disorder resulting in ulcerated wounds.
• Diabetes mellitus.
• Pregnancy or breastfeeding during the study (a urine pregnancy test was performed at screening for female participants of childbearing potential).
• Females of childbearing potential who were not abstinent and not practicing a medically acceptable method of contraception.
• Known history of cardiac, hepatic, or renal disease.